Key Points
- BioNTech CEO Ugur Sahin sold 30,000 shares at an average price of $99.40, generating approximately $2.98 million. The transaction occurred under a pre-arranged Rule 10b5-1 trading plan, leaving him with 380,209 shares.
- Sahin has made a series of additional BioNTech sales since September 10, totaling hundreds of thousands of shares, indicating continued insider selling over the period.
- BioNTech recently reported weaker-than-expected quarterly results, including a $2.53 per-share loss and revenue down 59.5% year over year. Despite mixed analyst actions, the stock carries a consensus “Moderate Buy” rating with a $126 target price.
BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 30,000 shares of the business's stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $99.40, for a total value of $2,982,000.00. Following the completion of the transaction, the chief executive officer directly owned 380,209 shares in the company, valued at approximately $37,792,774.60. This trade represents a 7.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ugur Sahin also recently made the following trade(s):
- On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total transaction of $3,860,610.00.
- On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total transaction of $4,633,120.00.
- On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The stock was sold at an average price of $97.81, for a total transaction of $3,227,730.00.
- On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total transaction of $2,886,600.00.
- On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total transaction of $3,352,400.00.
- On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total transaction of $1,441,350.00.
- On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total value of $3,280,660.00.
- On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total value of $4,077,450.00.
- On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $96.93, for a total value of $4,361,850.00.
- On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total value of $1,974,355.00.
BioNTech Stock Up 0.8%
BNTX stock opened at $99.26 on Friday. The stock's 50 day simple moving average is $98.03 and its 200 day simple moving average is $94.76. The company has a market cap of $25.10 billion, a P/E ratio of -12.68 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00.
BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. During the same quarter in the prior year, the firm earned ($1.60) EPS. The company's revenue was down 59.5% compared to the same quarter last year. On average, research analysts expect that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
BNTX has been the topic of several recent research reports. Canaccord Genuity Group dropped their price target on shares of BioNTech from $142.00 to $136.00 and set a "buy" rating on the stock in a research report on Monday, August 31st. Sanford C. Bernstein reissued a "market perform" rating on shares of BioNTech in a report on Friday, June 5th. BMO Capital Markets lowered BioNTech from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $128.00 to $105.00 in a report on Tuesday, September 8th. Citigroup dropped their target price on BioNTech from $130.00 to $125.00 and set a "buy" rating on the stock in a report on Wednesday, August 5th. Finally, Wall Street Zen downgraded BioNTech from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.
Check Out Our Latest Stock Report on BNTX
Institutional Trading of BioNTech
A number of institutional investors and hedge funds have recently modified their holdings of the business. Engineers Gate Manager LP lifted its holdings in BioNTech by 17.3% during the second quarter. Engineers Gate Manager LP now owns 12,433 shares of the company's stock worth $1,157,000 after acquiring an additional 1,833 shares during the period. Integrated Wealth Concepts LLC bought a new position in BioNTech in the 2nd quarter valued at $39,000. Nykredit A S purchased a new stake in shares of BioNTech during the 2nd quarter valued at $293,000. B. Metzler seel. Sohn & Co. AG increased its position in shares of BioNTech by 66.7% during the 2nd quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company's stock valued at $1,020,000 after purchasing an additional 4,390 shares during the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of BioNTech during the 2nd quarter worth $2,520,000. 15.52% of the stock is owned by hedge funds and other institutional investors.
About BioNTech
(
Get Free Report)
BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.
The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.
BioNTech was founded in 2008 and is headquartered in Mainz, Germany.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
